Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

Cyriel Y. Ponsioen, Keith Lindor, Ruby Mehta, Lara Dimick-Santos

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 00:000-000).

Original languageEnglish (US)
Pages (from-to)1174-1188
Number of pages15
Issue number3
StatePublished - Sep 2018

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis'. Together they form a unique fingerprint.

Cite this